RXRX
$3.18
$-0.12 (-3.63%)-3.63%
OpenLoading chart...
IndexN/A
Market Cap1.67B
Enterprise Value1.16B
Income$-0.20B
Sales$0.01B
EmployeesN/A
P/E-3.06
P/S24.50
P/B1.62
P/C-4.84
EV/EBITDA-2.08
EV/SalesN/A
EPS (ttm)-1.04
EarningsN/A
Gross Margin-61.96%
Oper. Margin-867.87%
Profit Margin-863.35%
Volume7.34M
Shs Outstand0.52B
Change-3.78%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $58.84M | $43.88M | $39.68M | $10.00M | $3.41M | $1.71M |
| Cost of Revenue | $45.24M | $42.59M | $48.27M | $0.00 | $0.00 | $45.81M |
| Gross Profit | $13.60M | $1.29M | $-8.59M | $10.00M | $3.41M | $-44.10M |
| Gross Margin | 23.12% | 2.94% | -21.66% | 100.00% | 100.00% | -2577.32% |
| Operating Expenses | $492.61M | $351.35M | $237.13M | $192.78M | $88.03M | $18.34M |
| Operating Income | $-479.00M | $-350.06M | $-245.73M | $-182.78M | $-84.61M | $-62.44M |
| Operating Margin | -814.09% | -797.84% | -619.26% | -1827.75% | -2479.20% | -3649.39% |
| Net Income | $-463.66M | $-328.07M | $-239.48M | $-186.48M | $-87.01M | $-62.52M |
| Net Margin | -788.02% | -747.71% | -603.50% | -1864.79% | -2549.25% | -3654.30% |
| EPS (Basic) | $-1.69 | $-1.58 | $-1.36 | $-1.05 | $-0.52 | $-0.37 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $1.45B | $653.70M | $701.29M | $610.35M | $298.58M | $101.43M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $413.82M | $190.26M | $215.48M | $67.41M | $504.87M | $225.70M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.03B | $463.44M | $485.81M | $542.94M | $-206.29M | $-124.27M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.03B | $463.44M | $485.81M | $542.94M | $-206.29M | $-124.27M |
| Total Liabilities & Stockholders Equity | $1.45B | $653.70M | $701.29M | $610.35M | $298.58M | $101.43M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-463.66M | $-328.07M | $-239.48M | $-186.48M | $-87.01M | $-62.52M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-359.17M | $-287.78M | $-83.52M | $-158.61M | $-45.40M | $-57.04M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision MedicineGlobeNewswire Inc. Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesGlobeNewswire Inc. 3 Stocks With the Most Upside by the End of 2026The Motley Fool 2 Beaten-Down Stocks That Still Aren't Worth BuyingThe Motley Fool Generative AI in Drug Discovery: Revolutionizing Pharmaceutical Research and DevelopmentGlobeNewswire Inc. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?The Motley Fool Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion MarketThe Motley Fool
Show 12 more stories
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider BuyingThe Motley Fool The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItBenzinga Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?The Motley Fool Global AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsightGlobeNewswire Inc. 3 Stocks Poised to Disrupt the Healthcare Market by 2030The Motley Fool Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech PlatformGlobeNewswire Inc. Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026The Motley Fool ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025Benzinga Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool Can This Beaten-Down AI Stock Bounce Back in 2026?The Motley Fool Why Recursion Pharamaceuticals Topped the Market TodayThe Motley Fool
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Discover more
You may be interested in